for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Provention Bio Inc

PRVB.O

Latest Trade

7.13USD

Change

0.38(+5.63%)

Volume

554,101

Today's Range

6.72

 - 

7.26

52 Week Range

6.14

 - 

20.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.75
Open
6.80
Volume
554,101
3M AVG Volume
27.02
Today's High
7.26
Today's Low
6.72
52 Week High
20.05
52 Week Low
6.14
Shares Out (MIL)
63.37
Market Cap (MIL)
427.78
Forward P/E
-3.19
Dividend (Yield %)
--

Next Event

Q2 2021 Provention Bio Inc Earnings Release

Latest Developments

More

Provention Bio Reports Q1 Loss Per Share $0.52

Provention Bio Provides Additional Regulatory Update On Biologics License Application For Teplizumab

Provention Bio Reports Fourth Quarter And Full Year 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.

Industry

Biotechnology & Drugs

Contact Info

55 BROAD STREET, 2ND FLOOR

RED BANK, NJ

07701

United States

+1.908.4289136

https://www.proventionbio.com/

Executive Leadership

Wayne F. Pisano

Independent Chairman of the Board

Ashleigh Palmer

President, Chief Executive Officer, Co-Founder, Director

Francisco Leon

Co-Founder, Chief Scientific Officer

Andrew T. Drechsler

Chief Financial Officer

Jason Hoitt

Chief Commercial Officer

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.190

2019

-1.060

2020

-1.880

2021(E)

-2.116
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-91.73
Return on Equity (TTM)
-81.15

Latest News

Latest News

BRIEF-Provention Bio Announces Pricing Of 6.60 Mln Common Shares At $14.50 Per Share

* PROVENTION BIO ANNOUNCES PRICING OF $95.7 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Provention Bio Announces Proposed Public Offering Of Common Stock

* PROVENTION BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Provention Bio's Teplizumab Continued To Delay The Onset Of Insulin-Dependent Type 1 Diabetes

* PROVENTION BIO'S TEPLIZUMAB CONTINUED TO SIGNIFICANTLY DELAY THE ONSET OF INSULIN-DEPENDENT TYPE 1 DIABETES (T1D) IN PRESYMPTOMATIC PATIENTS

BRIEF-Provention Bio And Vactech Announce Publication Of Proof-Of-Concept Data For A Preclinical Prototype Of Coxsackievirus B Vaccine

* PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR A PRECLINICAL PROTOTYPE OF COXSACKIEVIRUS B VACCINE

BRIEF-Provention Bio Q1 Loss Per Share $0.26

* PROVENTION BIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Provention Bio Initiates Rolling Submission Of BLA For Teplizumab For The Delay Or Prevention Of Clinical Type 1 Diabetes In At-Risk Individuals

* PROVENTION BIO INITIATES ROLLING SUBMISSION OF BIOLOGIC LICENSE APPLICATION FOR TEPLIZUMAB FOR THE DELAY OR PREVENTION OF CLINICAL TYPE 1 DIABETES IN AT-RISK INDIVIDUALS

BRIEF-Provention Bio Reports Q4 Loss Per Share Of $0.22

* PROVENTION BIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Provention Announces Positive Data From Phase 1B Prevail Study Of PRV-3279

* PROVENTION ANNOUNCES POSITIVE DATA FROM PHASE 1B PREVAIL STUDY OF PRV-3279

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up